Johnson Controls announces $9B increase to share repurchase program
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
18 minutes ago
- Bloomberg
Hong Kong Bourse Consults on Cutting Settlement for Trades to One Day
Hong Kong proposed to half the time it takes to settle stock trades to one day to align better with international and mainland Chinese standards. The city proposed to move to so-called T+1 from T+2, according to a consultation paper issued by the Hong Kong Exchanges & Clearing Ltd. on Wednesday. There was no time period given for the change, but industry participants were asked to submit feedback on the paper by Sept. 1.
Business Wire
2 hours ago
- Business Wire
Circus SE Appoints Former Bundeswehr Officer as VP Defense Strategy & Operations
MUNICH--(BUSINESS WIRE)--Circus SE (XETRA: CA1), a global technology leader in AI software and robotics for the food service industry, announces the appointment of Jan Hesselbarth as Vice President Defense Strategy & Operations. Hesselbarth brings over two decades of leadership across military operations and public-sector transformation. As a former airborne officer and senior advisor to federal and international institutions, he has led military and civil programs with teams of up to 1,000 personnel and delivered results across highly dynamic and complex environments. At Circus, Hesselbarth will take full strategic and operational ownership of defense deployment programs, including deployments of the recently introduced CA-M autonomous meal supply system for armed forces and civil protection. His scope spans logistics, deployment, and compliance in security-critical environments. Prior to joining Circus, Hesselbarth advised military commands and national authorities on geostrategy, resilience, and security. Throughout his career, he trained over 5,000 Bundeswehr personnel in mission-specific readiness, supported operational planning for Lithuanian officer training and German command structures, and co-authored a federal study on maritime security for the German Ministry of the Interior. 'Jan combines operational command experience with strategic foresight – a rare profile at the intersection of defense, logistics, and innovation,' said Nikolas Bullwinkel, CEO and Founder of Circus. As Circus ramps up its defense unit, Hesselbarth's appointment reflects the company's commitment to operational readiness, secure field logistics, and customer-centric deployment – both in Europe and globally. 'I'm excited to join Circus at this inflection point,' said Jan Hesselbarth. 'Bringing autonomous technology into real-world military and security operations requires more than innovation – it takes field experience, discipline, and trust. I look forward to building systems that deliver.' About Circus SE Circus SE (XETRA: CA1) is a global AI and robotics company developing autonomous systems for food supply in both civilian and defense sectors. Its flagship robot, the patented CA-1, is the world's first fully autonomous food production robot, now in serial production. Powered by proprietary embodied AI, Circus delivers industrial-scale, high-reliability meal output with minimal human input. Headquartered in Munich, the company is building the global infrastructure for autonomous food supply – on a mission to fuel humanity.
Business Wire
5 hours ago
- Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis
LILLE, France & PARIS--(BUSINESS WIRE)--4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. 'Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,' said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. 'Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. By acting directly in the joint, 4P004 tackles pain, inflammation, and tissue damage through GLP-1-mediated pathways. We believe its targeted intra-articular delivery can unlock the full therapeutic power of GLP-1 biology. We are eager to confirm both symptomatic relief and meaningful structural benefit in this proof-of-concept study'. The study's primary endpoint is the reduction in knee pain at week 4 and 12. Key secondary objectives include assessing synovial changes by contrast-enhanced MRI and conducting an exploratory analysis of blood and imaging biomarkers as potential surrogates for long-term disease progression and delay to total knee replacement. The study timeline covers 12 months, with patient enrollment taking place over 9 months and follow-up to be completed before the topline readout in the second half of 2026. INFLAM MOTION has been designed to generate the first human evidence that 4P004 can deliver both clinical relief and measurable structural benefit. Insights from this Phase 2a readout will shape the forthcoming Phase 2b program, whose primary aim will be to confirm surrogate endpoints that reliably predict the hard endpoint that is delaying the time to total knee replacement. About 4MB Incorporated in mid-2020 as a spin-off of 4P-Pharma, 4MB is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France. Website: LinkedIn: The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
